Shopping Cart 0
Cart Subtotal
USD 0

Psoriatic Arthritis Treatment Market by Drug Type (NSAIDs, DMARDs, Biologics, and Others), Type (Prescription, and OTC), and Route of Administration (Topical, Oral, and Injectable): Global Opportunity Analysis and Industry Forecast, 2019-2026

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 5370

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 8995

Details

The psoriatic arthritis treatment market was valued at USD 7,860 million in 2018, and is estimated to reach at USD 13,744 million by 2026, registering a CAGR of 7.2% from 2019 to 2026.
 
Psoriatic arthritis is an autoimmune disease caused by an attack of body's immune system on skin and joint. The disease is characterized by stiffness, swelling in the joints, and pain. Symmetric psoriatic arthritis, asymmetric psoriatic arthritis, spondylitis, distal psoriatic arthritis, and arthritis mutilans are the different types of psoriatic arthritis. Symptoms associated with this disorder include low back pain, conjunctivitis, swollen joint, nail pitting, and foot pain. The disorder is more prevalent among patients already suffering from psoriasis. Psoriatic arthritis can be diagnosed with tests such as rheumatoid factor (RF), joint fluid test, X-ray, and magnetic resonance imaging (MRI). Drugs used to treat psoriatic arthritis disease include NSAIDs, disease-modifying antirheumatic drugs (DMARDs), biologics, immunosuppressant drugs, and others.
 
Significant increase in prevalence of psoriatic arthritis, rise in demand for psoriatic arthritis pharmacotherapy, strong pipeline of biosimilar & biologic products, stressful lifestyle resulting in the overstimulation of immune system, and rise in geriatric population are the key factors that fuel the growth of the global psoriatic arthritis treatment market. Moreover, rise in adoption of psoriatic arthritis treatment medications, increase in R&D activities to develop new products for effective treatment of psoriatic arthritis, frequent product launches by key players, surge in awareness toward availability of treatment for psoriatic arthritis, and increase in risk of diseases are other factors that contribute toward the growth of the market. However, lack of standardization tools for diagnosis and high cost of treatment are expected to hamper the market growth.
 
The global psoriatic arthritis treatment market is segmented into drug type, type, route of administration, and region. By drug type, the market is categorized into NSAIDs, DMARDs, biologics, and others. On the basis of type, the market is divided into prescription, and OTC. According to route of administration, it is segregated into topical, oral, and injectable. Region wise, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa and rest of LAMEA).
 
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
 
KEY MARKET SEGMENTS
By Drug Type
NSAIDs
DMARDs
Biologics
Others
By Type
Prescription
OTC
By Route of Administration
Topical
Oral
Injectable
By Region
 
North America
o U.S.
o Canada
o Mexico
Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
Asia-Pacific
o Japan
o China
o Australia
o India
o South Korea
o Rest of Asia-Pacific
LAMEA
o Brazil
o Saudi Arabia
o South Africa
o Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Company
Celgene Corporation
Eli Lilly And Company
Johnson & Johnson
Merck & Co Inc.
Novartis AG
Pfizer Inc.
UCB S.A.
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
F. Hoffmann-La Roche AG
Valeant Pharmaceuticals International, Inc.
Abbott Laboratories
READ MORE

Table Of Content

Scope

Chapter 1: Introduction

 

1.1. Report Description

1.2. Key Benefits For Stakeholders

1.3. Key Market Segments

 

1.3.1. List of Key Players Profiled In The Report

 

1.4. Research Methodology

 

1.4.1. Secondary Research

1.4.2. Primary Research

1.4.3. Analyst Tools And Models

 

Chapter 2: Executive Summary

 

2.1. Key Findings of The Study

2.2. Cxo Perspective

 

Chapter 3: Market Overview

 

3.1. Market Definition And Scope

3.2. Key Findings

 

3.2.1. Top Investment Pockets

 

3.3. Porter'S Five Force Analysis

3.4. Market Dynamics

 

3.4.1. Drivers

 

3.4.1.1. Rise In Prevalence of Psoriasis & Psoriatic Arthritis Disease

3.4.1.2. Increase In Number of Pipeline Drugs

3.4.1.3. Increase In Government Expenditure On Healthcare

 

3.4.2. Restraint

 

3.4.2.1. Poor Demand In Under Developed Countries

 

3.4.3. Opportunities

 

3.4.3.1. Growth Opportunities In Emerging Markets

 

3.4.4. Impact Analysis

 

Chapter 4: Psoriatic Arthritis Treatment Market, By Drug Type

 

4.1. Overview

 

4.1.1. Market Size And Forecast

 

4.2. Nsaids

 

4.2.1. Key Market Trends, Growth Factors, And Opportunities

4.2.2. Market Size And Forecast, By Region

4.2.3. Market Analysis, By Country

 

4.3. Dmards

 

4.3.1. Key Market Trends, Growth Factors, And Opportunities

4.3.2. Market Size And Forecast

4.3.3. Market Analysis, By Country

 

4.4. Biologics

 

4.4.1. Key Market Trends, Growth Factors, And Opportunities

4.4.2. Market Size And Forecast

4.4.3. Market Analysis, By Country

 

4.5. Others

 

4.5.1. Key Market Trends, Growth Factors, And Opportunities

4.5.2. Market Size And Forecast

4.5.3. Market Analysis, By Country

 

Chapter 5: Psoriatic Arthritis Treatment Market, By Type

 

5.1. Overview

 

5.1.1. Market Size And Forecast

 

5.2. Prescription

 

5.2.1. Market Size And Forecast, By Region

5.2.2. Market Analysis, By Country

 

5.3. Otc

 

5.3.1. Market Size And Forecast, By Region

5.3.2. Market Analysis, By Country

 

Chapter 6: Psoriatic Arthritis Treatment Market, By Route of Administration

 

6.1. Overview

 

6.1.1. Market Size And Forecast

 

6.2. Injectable

 

6.2.1. Market Size And Forecast, By Region

6.2.2. Market Analysis, By Country

 

6.3. Oral

 

6.3.1. Market Size And Forecast, By Region

6.3.2. Market Analysis, By Country

 

6.4. Topical

 

6.4.1. Market Size And Forecast, By Region

6.4.2. Market Analysis, By Country

 

Chapter 7: Psoriatic Arthritis Treatment Market, By Region

 

7.1. Overview

 

7.1.1. Market Size And Forecast

 

7.2. North America

 

7.2.1. Key Market Trends, Growth Factors, And Opportunities

7.2.2. Market Size And Forecast, By Country

 

7.2.2.1. U.S.

 

7.2.2.1.1. U.S. Psoriatic Arthritis Treatment Market, By Drug Type

7.2.2.1.2. U.S. Psoriatic Arthritis Treatment Market, By Type

7.2.2.1.3. U.S. Psoriatic Arthritis Treatment Market, By Route of Administration

 

7.2.2.2. Canada

 

7.2.2.2.1. Canada Psoriatic Arthritis Treatment Market, By Drug Type

7.2.2.2.2. Canada Psoriatic Arthritis Treatment Market, By Type

7.2.2.2.3. Canada Psoriatic Arthritis Treatment Market, By Route of Administration

 

7.2.2.3. Mexico

 

7.2.2.3.1. Mexico Psoriatic Arthritis Treatment Market, By Drug Type

7.2.2.3.2. Mexico Psoriatic Arthritis Treatment Market, By Type

7.2.2.3.3. Mexico Psoriatic Arthritis Treatment Market, By Route of Administration

 

7.2.3. North America Market Size And Forecast, By Drug Type

7.2.4. North America Market Size And Forecast, By Type

7.2.5. North America Market Size And Forecast, By Route of Administration

 

7.3. Europe

 

7.3.1. Key Market Trends, Growth Factors, And Opportunities

7.3.2. Market Size And Forecast, By Country

 

7.3.2.1. Germany

 

7.3.2.1.1. Germany Psoriatic Arthritis Treatment Market, By Drug Type

7.3.2.1.2. Germany Psoriatic Arthritis Treatment Market, By Type

7.3.2.1.3. Germany Psoriatic Arthritis Treatment Market, By Route of Administration7.3.2.2. France

7.3.2.2.1. France Psoriatic Arthritis Treatment Market, By Drug Type

7.3.2.2.2. France Psoriatic Arthritis Treatment Market, By Type

7.3.2.2.3. France Psoriatic Arthritis Treatment Market, By Route of Administration

 

7.3.2.3. Uk

 

7.3.2.3.1. Uk Psoriatic Arthritis Treatment Market, By Drug Type

7.3.2.3.2. Uk Psoriatic Arthritis Treatment Market, By Type

7.3.2.3.3. Uk Psoriatic Arthritis Treatment Market, By Route of Administration

 

7.3.2.4. Italy

 

7.3.2.4.1. Italy Psoriatic Arthritis Treatment Market, By Drug Type

7.3.2.4.2. Italy Psoriatic Arthritis Treatment Market, By Type

7.3.2.4.3. Italy Psoriatic Arthritis Treatment Market, By Route of Administration

 

7.3.2.5. Spain

 

7.3.2.5.1. Spain Psoriatic Arthritis Treatment Market, By Drug Type

7.3.2.5.2. Spain Psoriatic Arthritis Treatment Market, By Type

7.3.2.5.3. Spain Psoriatic Arthritis Treatment Market, By Route of Administration

 

7.3.2.6. Rest of Europe

 

7.3.2.6.1. Rest of Europe Psoriatic Arthritis Treatment Market, By Drug Type

7.3.2.6.2. Rest of Europe Psoriatic Arthritis Treatment Market, By Type

7.3.2.6.3. Rest of Europe Psoriatic Arthritis Treatment Market, By Route of Administration

 

7.3.3. Europe Market Size And Forecast, By Drug Type

7.3.4. Europe Market Size And Forecast, By Type

7.3.5. Europe Market Size And Forecast, By Route of Administration

 

7.4. Asia-Pacific

 

7.4.1. Key Market Trends, Growth Factors, And Opportunities

7.4.2. Market Size And Forecast, By Country

 

7.4.2.1. Japan

 

7.4.2.1.1. Japan Psoriatic Arthritis Treatment Market, By Drug Type

7.4.2.1.2. Japan Psoriatic Arthritis Treatment Market, By Type

7.4.2.1.3. Japan Psoriatic Arthritis Treatment Market, By Route of Administration

 

7.4.2.2. China

 

7.4.2.2.1. China Psoriatic Arthritis Treatment Market, By Drug Type

7.4.2.2.2. China Psoriatic Arthritis Treatment Market, By Type

7.4.2.2.3. China Psoriatic Arthritis Treatment Market, By Route of Administration

 

7.4.2.3. Australia

 

7.4.2.3.1. Australia Psoriatic Arthritis Treatment Market, By Drug Type

7.4.2.3.2. Australia Psoriatic Arthritis Treatment Market, By Type

7.4.2.3.3. Australia Psoriatic Arthritis Treatment Market, By Route of Administration

 

7.4.2.4. India

 

7.4.2.4.1. India Psoriatic Arthritis Treatment Market, By Drug Type

7.4.2.4.2. India Psoriatic Arthritis Treatment Market, By Type

7.4.2.4.3. India Psoriatic Arthritis Treatment Market, By Route of Administration

 

7.4.2.5. South Korea

 

7.4.2.5.1. South Korea Psoriatic Arthritis Treatment Market, By Drug Type

7.4.2.5.2. South Korea Psoriatic Arthritis Treatment Market, By Type

7.4.2.5.3. South Korea Psoriatic Arthritis Treatment Market, By Route of Administration

 

7.4.2.6. Rest of Asia-Pacific

 

7.4.2.6.1. Rest of Asia-Pacific Psoriatic Arthritis Treatment Market, By Drug Type

7.4.2.6.2. Rest of Asia-Pacific Psoriatic Arthritis Treatment Market, By Type

7.4.2.6.3. Rest of Asia-Pacific Psoriatic Arthritis Treatment Market, By Route of Administration

 

7.4.3. Asia-Pacific Market Size And Forecast, By Drug Type

7.4.4. Asia-Pacific Market Size And Forecast, By Type

7.4.5. Asia-Pacific Market Size And Forecast, By Route of Administration

 

7.5. Lamea

 

7.5.1. Key Market Trends, Growth Factors, And Opportunities

7.5.2. Market Size And Forecast, By Country

 

7.5.2.1. Brazil

 

7.5.2.1.1. Brazil Psoriatic Arthritis Treatment Market, By Drug Type

7.5.2.1.2. Brazil Psoriatic Arthritis Treatment Market, By Type

7.5.2.1.3. Brazil Psoriatic Arthritis Treatment Market, By Route of Administration

 

7.5.2.2. Saudi Arabia

 

7.5.2.2.1. Saudi Arabia Psoriatic Arthritis Treatment Market, By Drug Type

7.5.2.2.2. Saudi Arabia Psoriatic Arthritis Treatment Market, By Type

7.5.2.2.3. Saudi Arabia Psoriatic Arthritis Treatment Market, By Route of Administration

 

7.5.2.3. South Africa

 

7.5.2.3.1. South Africa Psoriatic Arthritis Treatment Market, By Drug Type

7.5.2.3.2. South Africa Psoriatic Arthritis Treatment Market, By Type

7.5.2.3.3. South Africa Psoriatic Arthritis Treatment Market, By Route of Administration

 

7.5.2.4. Rest of Lamea

 

7.5.2.4.1. Rest of Lamea Psoriatic Arthritis Treatment Market, By Drug Type

7.5.2.4.2. Rest of Lamea Psoriatic Arthritis Treatment Market, By Type

7.5.2.4.3. Rest of Lamea Psoriatic Arthritis Treatment Market, By Route of Administration

 

7.5.3. Lamea Market Size And Forecast, By Drug Type

7.5.4. Lamea Market Size And Forecast, By Type

7.5.5. Lamea Market Size And Forecast, By Route of Administration

 

Chapter 8: Company Profiles

 

8.1. Abbvie Inc.

 

8.1.1. Company Overview

8.1.2. Company Snapshot

8.1.3. Operating Business Segments

8.1.4. Product Portfolio

8.1.5. Business Performance

8.1.6. Key Strategic Moves And Developments

 

8.2. Amgen Inc.

 

8.2.1. Company Overview

8.2.2. Company Snapshot

8.2.3. Operating Business Segments

8.2.4. Product Portfolio

8.2.5. Business Performance

8.2.6. Key Strategic Moves And Developments

 

8.3. Bristol-Myers Squibb Company

 

8.3.1. Company Overview

8.3.2. Company Snapshot

8.3.3. Operating Business Segments

8.3.4. Product Portfolio

8.3.5. Business Performance

8.3.6. Key Strategic Moves And Developments

 

8.4. Eli Lilly And Company.

 

8.4.1. Company Overview

8.4.2. Company Snapshot

8.4.3. Operating Business Segments

8.4.4. Product Portfolio

8.4.5. Business Performance

8.4.6. Key Strategic Moves And Developments

 

8.5. Johnson & Johnson.

 

8.5.1. Company Overview

8.5.2. Company Snapshot

8.5.3. Operating Business Segments

8.5.4. Product Portfolio

8.5.5. Business Performance

8.5.6. Key Strategic Moves And Developments

 

8.6. Merck & Co Inc.

 

8.6.1. Company Overview

8.6.2. Company Snapshot

8.6.3. Operating Business Segments

8.6.4. Product Portfolio

8.6.5. Business Performance

 

8.7. Mylan N.V

 

8.7.1. Company Overview

8.7.2. Company Snapshot

8.7.3. Operating Business Segments

8.7.4. Product Portfolio

8.7.5. Business Performance

 

8.8. Novartis Ag

 

8.8.1. Company Overview

8.8.2. Company Snapshot

8.8.3. Operating Business Segments

8.8.4. Product Portfolio

8.8.5. Business Performance

 

8.9. Pfizer Inc.

 

8.9.1. Company Overview

8.9.2. Company Snapshot

8.9.3. Operating Business Segments

8.9.4. Product Portfolio

8.9.5. Business Performance

 

8.10. Ucb S.A.

 

8.10.1. Company Overview

8.10.2. Company Snapshot

8.10.3. Operating Business Segments

8.10.4. Product Portfolio

8.10.5. Business Performance


List Of Figure

List of Figures

 

Figure 01. Global Psoriatic Arthritis Treatment Market Segmentation

Figure 02. Top Investment Pockets

Figure 03. High Bargaining Power of Suppliers

Figure 04. Moderate Bargaining Power of Buyers

Figure 05. High Threat of Substitutes

Figure 06. Moderate Threat of New Entrants

Figure 07. High Intensity of Rivalry

Figure 08. Impact Analysis

Figure 09. Comparative Analysis of Nsaids Psoriatic Arthritis Treatment Market, By Country, 2018 & 2026 (USD Million)

Figure 10. Comparative Analysis of Dmards Psoriatic Arthritis Treatment Market, By Country, 2018 & 2026 (USD Million)

Figure 11. Comparative Analysis of Biologics Psoriatic Arthritis Treatment Market, By Country, 2018 & 2026 (USD Million)

Figure 12. Comparative Analysis of Others Psoriatic Arthritis Treatment Market, By Country, 2018 & 2026 (USD Million)

Figure 13. Comparative Analysis of Prescription Psoriatic Arthritis Treatment Market, By Country, 2018 & 2026 (USD Million)

Figure 14. Comparative Analysis of Otc Psoriatic Arthritis Treatment Market, By Country, 2018 & 2026 (USD Million)

Figure 15. Comparative Analysis of Injectable Psoriatic Arthritis Treatment Market, By Country, 2018 & 2026 (USD Million)

Figure 16. Comparative Analysis of Oral Psoriatic Arthritis Treatment Market, By Country, 2018 & 2026 (USD Million)

Figure 17. Comparative Analysis of Topical Psoriatic Arthritis Treatment Market, By Country, 2018 & 2026 (USD Million)

Figure 18. Abbvie Inc: Net Sales, 2016-2018 (USD Million)

Figure 19. Abbvie Inc: Revenue Share By Segment, 2018 (%)

Figure 20. Abbvie Inc: Revenue Share By Region, 2018(%)

Figure 21. Amgen: Net Sales, 2016-2018 (USD Million)

Figure 22. Amgen: Revenue Share By Region, 2018(%)

Figure 23. Bms: Net Sales, 2016-2018 (USD Million)

Figure 24. Bms: Revenue Share By Region, 2018(%)

Figure 25. Lilly: Net Sales, 2016-2018 (USD Million)

Figure 26. Lilly: Revenue Share By Segment, 2018 (%)

Figure 27. Lilly: Revenue Share By Region, 2018(%)

Figure 28. J&J: Net Sales, 2016-2018 (USD Million)

Figure 29. J&J: Revenue Share By Segment, 2018 (%)

Figure 30. J&J: Revenue Share By Geography, 2018 (%)

Figure 31. Merck & Co., Inc: Net Sales, 2016-2018 (USD Million)

Figure 32. Merck & Co., Inc: Revenue Share By Segment, 2018 (%)

Figure 33. Merck & Co., Inc: Revenue Share By Geography, 2018 (%)

Figure 34. Mylan: Net Sales, 2016-2018 (USD Million)

Figure 35. Mylan: Revenue Share By Geography, 2018 (%)

Figure 36. Novartis Ag: Net Sales, 2016-2018 (USD Million)

Figure 37. Novartis Ag: Revenue Share By Segment, 2018 (%)

Figure 38. Novartis Ag: Revenue Share By Region, 2018(%)

Figure 39. Pfizer Inc: Net Sales, 2016-2018 (USD Million)

Figure 40. Pfizer Inc: Revenue Share By Segment, 2018 (%)

Figure 41. Pfizer Inc: Revenue Share By Region, 2018(%)

Figure 42. Ucb S.A.: Net Sales, 2016-2018 (USD Million)

Figure 43. Ucb S.A.: Revenue Share By Segment, 2018 (%)

Figure 44. Ucb S.A.: Revenue Share By Geography, 2018 (%)


List Of Table

List of Tables

 

Table 01. Global Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026 (USD Million)

Table 02. Nsaids Psoriatic Arthritis Treatment Market, By Region, 2018-2026 (USD Million)

Table 03. Dmards Psoriatic Arthritis Treatment Market, By Region, 2018-2026 (USD Million)

Table 04. Biologics Psoriatic Arthritis Treatment Market, By Region, 2018-2026 (USD Million)

Table 05. Others Psoriatic Arthritis Treatment Market, By Region, 2018-2026 (USD Million)

Table 06. Global Psoriatic Arthritis Treatment Market, By Type, 2018-2026 (USD Million)

Table 07. Prescription Psoriatic Arthritis Treatment Market, By Region, 2018-2026 (USD Million)

Table 08. Otc Psoriatic Arthritis Treatment Market, By Region, 2018-2026 (USD Million)

Table 09. Global Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026 (USD Million)

Table 10. Injectable Psoriatic Arthritis Treatment Market, By Region, 2018-2026 (USD Million)

Table 11. Oral Psoriatic Arthritis Treatment Market, By Region, 2018-2026 (USD Million)

Table 12. Topical Psoriatic Arthritis Treatment Market, By Region, 2018-2026 (USD Million)

Table 13. Psoriatic Arthritis Treatment Market, By Region, 2018-2026 (USD Million)

Table 14. North America Psoriatic Arthritis Treatment Market, By Country, 2018-2026 (USD Million)

Table 15. U.S. Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026

Table 16. U.S. Psoriatic Arthritis Treatment Market, By Type, 2018-2026

Table 17. U.S. Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026

Table 18. Canada Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026

Table 19. Canada Psoriatic Arthritis Treatment Market, By Type, 2018-2026

Table 20. Canada Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026

Table 21. Mexico Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026

Table 22. Mexico Psoriatic Arthritis Treatment Market, By Type, 2018-2026

Table 23. Mexico Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026

Table 24. North America Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026

Table 25. North America Psoriatic Arthritis Treatment Market, By Type, 2018-2026

Table 26. North America Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026

Table 27. Europe Psoriatic Arthritis Treatment Market, By Country, 2018-2026 (USD Million)

Table 28. Germany Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026

Table 29. Germany Psoriatic Arthritis Treatment Market, By Type, 2018-2026

Table 30. Germany Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026

Table 31. France Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026

Table 32. France Psoriatic Arthritis Treatment Market, By Type, 2018-2026

Table 33. France Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026

Table 34. Uk Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026

Table 35. Uk Psoriatic Arthritis Treatment Market, By Type, 2018-2026

Table 36. Uk Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026

Table 37. Italy Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026

Table 38. Italy Psoriatic Arthritis Treatment Market, By Type, 2018-2026

Table 39. Italy Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026

Table 40. Spain Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026

Table 41. Spain Psoriatic Arthritis Treatment Market, By Type, 2018-2026

Table 42. Spain Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026

Table 43. Rest of Europe Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026

Table 44. Rest of Europe Psoriatic Arthritis Treatment Market, By Type, 2018-2026

Table 45. Rest of Europe Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026

Table 46. Europe Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026

Table 47. Europe Psoriatic Arthritis Treatment Market, By Type, 2018-2026

Table 48. Europe Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026

Table 49. Asia-Pacific Psoriatic Arthritis Treatment Market, By Country, 2018-2026 (USD Million)

Table 50. Japan Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026

Table 51. Japan Psoriatic Arthritis Treatment Market, By Type, 2018-2026

Table 52. Japan Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026

Table 53. China Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026

Table 54. China Psoriatic Arthritis Treatment Market, By Type, 2018-2026

Table 55. China Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026

Table 56. Australia Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026

Table 57. Australia Psoriatic Arthritis Treatment Market, By Type, 2018-2026

Table 58. Australia Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026

Table 59. India Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026

Table 60. India Psoriatic Arthritis Treatment Market, By Type, 2018-2026

Table 61. India Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026

Table 62. South Korea Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026

Table 63. South Korea Psoriatic Arthritis Treatment Market, By Type, 2018-2026

Table 64. South Korea Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026

Table 65. Rest of Asia-Pacific Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026

Table 66. Rest of Asia-Pacific Psoriatic Arthritis Treatment Market, By Type, 2018-2026

Table 67. Rest of Asia-Pacific Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026

Table 68. Asia-Pacific Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026

Table 69. Asia-Pacific Psoriatic Arthritis Treatment Market, By Type, 2018-2026

Table 70. Asia-Pacific Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026

Table 71. Lamea Psoriatic Arthritis Treatment Market, By Country, 2018-2026 (USD Million)

Table 72. Brazil Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026

Table 73. Brazil Psoriatic Arthritis Treatment Market, By Type, 2018-2026

Table 74. Brazil Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026

Table 75. Saudi Arabia Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026

Table 76. Saudi Arabia Psoriatic Arthritis Treatment Market, By Type, 2018-2026

Table 77. Saudi Arabia Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026

Table 78. South Africa Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026

Table 79. South Africa Psoriatic Arthritis Treatment Market, By Type, 2018-2026

Table 80. South Africa Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026

Table 81. Rest of Lamea Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026

Table 82. Rest of Lamea Psoriatic Arthritis Treatment Market, By Type, 2018-2026

Table 83. Rest of Lamea Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026

Table 84. Lamea Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026

Table 85. Lamea Psoriatic Arthritis Treatment Market, By Type, 2018-2026

Table 86. Lamea Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026

Table 87. Abbvie Inc: Company Snapshot

Table 88. Abbvie Inc: Operating Segments

Table 89. Abbvie Inc: Product Portfolio

Table 90. Amgen: Company Snapshot

Table 91. Amgen: Product Segment

Table 92. Amgen: Product Portfolio

Table 93. Bms.: Operating Segment

Table 94. Bms.: Product Portfolio

Table 95. Lilly: Company Snapshot

Table 96. Lilly: Operating Segments

Table 97. Lilly: Product Portfolio

Table 98. J&J: Company Snapshot

Table 99. J&J: Operating Segments

Table 100. J&J: Product Portfolio

Table 101. Merck & Co., Inc: Company Snapshot

Table 102. Merck & Co., Inc: Operating Segments

Table 103. Merck & Co., Inc: Product Portfolio

Table 104. Mylan: Company Snapshot

Table 105. Mylan: Operating Segments

Table 106. Mylan: Product Portfolio

Table 107. Novartis Ag: Company Snapshot

Table 108. Novartis Ag: Operating Segments

Table 109. Novartis Ag: Product Portfolio

Table 110. Pfizer Inc: Company Snapshot

Table 111. Pfizer Inc: Operating Segments

Table 112. Pfizer Inc: Product Portfolio

Table 113. Ucb S.A.: Company Snapshot

Table 114. Ucb S.A.: Product Portfolio

Licence Rights

Single-User license:

This  grants one non-exclusive, non-transferable machine-readable license for the report either electronically or online. The right to store, display, use, or stockpile the report is restricted to only ONE authorized computer. For obtaining a single user license, ONLY an individual ("you") for individual use is entitled for using the product or as mentioned in the License Terms. Any individual representing an organization is refrained from accessing the products/services of AMR or as stated in the License Terms; any breach of which shall lead to violation of applicable laws in the United States, India, or in the jurisdiction of purchase. The products and services offered are the intellectual property of AMR, and are protected by applicable copyright laws, international treaty provisions, and other applicable laws of the country in which these are being used. Albeit the abovementioned, you are NOT be permitted to:

transmit or permit any third party to use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to assign the rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial/noncommercial gains

share the information or content either electronically or in printed form with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization or any other unauthorized users.

 

Five-User License:

This  grants up to Five non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online. The right to store, transfer, display, use, or stockpile the report is restricted to only FIVE authorized users. An individual representing an organization or an organization shall ONLY purchase the five-user license. The authorized users can print additional duplicate printed copies of the report for distribution to the employees of his/her company (Personnel). Albeit the abovementioned, you are NOT be permitted to:

 

transmit or permit by any means to any third party (i.e. non-personnel) or unauthorized users for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to redistribute or assign rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; exclusively permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial or noncommercial gains.

share the information or content either electronically or as printed copies with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization, or to more than 5 AUTHORIZED USERS.

 

Enterprise License:

This  grants global, non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online, within the organization and/or its subsidiaries. The authorized users shall have complete right to store, display, transfer, and/or use the report ONLY within the organization or its subsidiaries. Authorized users can take unlimited printed copies of the report for distribution among its employees. Albeit the abovementioned, you shall NOT be permitted to:

transmit or permit by any means to any third party (i.e. non-personnel) for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer or attempt to assign the rights in the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly And Company, Johnson & Johnson, Merck & Co Inc., Novartis AG, Pfizer Inc., and UCB S.A.

Company Profile

Company Profile Title

The psoriatic arthritis treatment market was valued at USD 7,860 million in 2018, and is estimated to reach at USD 13,744 million by 2026, registering a CAGR of 7.2% from 2019 to 2026.
 
Psoriatic arthritis is an autoimmune disease caused by an attack of body's immune system on skin and joint. The disease is characterized by stiffness, swelling in the joints, and pain. Symmetric psoriatic arthritis, asymmetric psoriatic arthritis, spondylitis, distal psoriatic arthritis, and arthritis mutilans are the different types of psoriatic arthritis. Symptoms associated with this disorder include low back pain, conjunctivitis, swollen joint, nail pitting, and foot pain. The disorder is more prevalent among patients already suffering from psoriasis. Psoriatic arthritis can be diagnosed with tests such as rheumatoid factor (RF), joint fluid test, X-ray, and magnetic resonance imaging (MRI). Drugs used to treat psoriatic arthritis disease include NSAIDs, disease-modifying antirheumatic drugs (DMARDs), biologics, immunosuppressant drugs, and others.
 
Significant increase in prevalence of psoriatic arthritis, rise in demand for psoriatic arthritis pharmacotherapy, strong pipeline of biosimilar & biologic products, stressful lifestyle resulting in the overstimulation of immune system, and rise in geriatric population are the key factors that fuel the growth of the global psoriatic arthritis treatment market. Moreover, rise in adoption of psoriatic arthritis treatment medications, increase in R&D activities to develop new products for effective treatment of psoriatic arthritis, frequent product launches by key players, surge in awareness toward availability of treatment for psoriatic arthritis, and increase in risk of diseases are other factors that contribute toward the growth of the market. However, lack of standardization tools for diagnosis and high cost of treatment are expected to hamper the market growth.
 
The global psoriatic arthritis treatment market is segmented into drug type, type, route of administration, and region. By drug type, the market is categorized into NSAIDs, DMARDs, biologics, and others. On the basis of type, the market is divided into prescription, and OTC. According to route of administration, it is segregated into topical, oral, and injectable. Region wise, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa and rest of LAMEA).
 
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
 
KEY MARKET SEGMENTS
By Drug Type
NSAIDs
DMARDs
Biologics
Others
By Type
Prescription
OTC
By Route of Administration
Topical
Oral
Injectable
By Region
 
North America
o U.S.
o Canada
o Mexico
Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
Asia-Pacific
o Japan
o China
o Australia
o India
o South Korea
o Rest of Asia-Pacific
LAMEA
o Brazil
o Saudi Arabia
o South Africa
o Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Company
Celgene Corporation
Eli Lilly And Company
Johnson & Johnson
Merck & Co Inc.
Novartis AG
Pfizer Inc.
UCB S.A.
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
F. Hoffmann-La Roche AG
Valeant Pharmaceuticals International, Inc.
Abbott Laboratories
READ MORE

Scope

Chapter 1: Introduction

 

1.1. Report Description

1.2. Key Benefits For Stakeholders

1.3. Key Market Segments

 

1.3.1. List of Key Players Profiled In The Report

 

1.4. Research Methodology

 

1.4.1. Secondary Research

1.4.2. Primary Research

1.4.3. Analyst Tools And Models

 

Chapter 2: Executive Summary

 

2.1. Key Findings of The Study

2.2. Cxo Perspective

 

Chapter 3: Market Overview

 

3.1. Market Definition And Scope

3.2. Key Findings

 

3.2.1. Top Investment Pockets

 

3.3. Porter'S Five Force Analysis

3.4. Market Dynamics

 

3.4.1. Drivers

 

3.4.1.1. Rise In Prevalence of Psoriasis & Psoriatic Arthritis Disease

3.4.1.2. Increase In Number of Pipeline Drugs

3.4.1.3. Increase In Government Expenditure On Healthcare

 

3.4.2. Restraint

 

3.4.2.1. Poor Demand In Under Developed Countries

 

3.4.3. Opportunities

 

3.4.3.1. Growth Opportunities In Emerging Markets

 

3.4.4. Impact Analysis

 

Chapter 4: Psoriatic Arthritis Treatment Market, By Drug Type

 

4.1. Overview

 

4.1.1. Market Size And Forecast

 

4.2. Nsaids

 

4.2.1. Key Market Trends, Growth Factors, And Opportunities

4.2.2. Market Size And Forecast, By Region

4.2.3. Market Analysis, By Country

 

4.3. Dmards

 

4.3.1. Key Market Trends, Growth Factors, And Opportunities

4.3.2. Market Size And Forecast

4.3.3. Market Analysis, By Country

 

4.4. Biologics

 

4.4.1. Key Market Trends, Growth Factors, And Opportunities

4.4.2. Market Size And Forecast

4.4.3. Market Analysis, By Country

 

4.5. Others

 

4.5.1. Key Market Trends, Growth Factors, And Opportunities

4.5.2. Market Size And Forecast

4.5.3. Market Analysis, By Country

 

Chapter 5: Psoriatic Arthritis Treatment Market, By Type

 

5.1. Overview

 

5.1.1. Market Size And Forecast

 

5.2. Prescription

 

5.2.1. Market Size And Forecast, By Region

5.2.2. Market Analysis, By Country

 

5.3. Otc

 

5.3.1. Market Size And Forecast, By Region

5.3.2. Market Analysis, By Country

 

Chapter 6: Psoriatic Arthritis Treatment Market, By Route of Administration

 

6.1. Overview

 

6.1.1. Market Size And Forecast

 

6.2. Injectable

 

6.2.1. Market Size And Forecast, By Region

6.2.2. Market Analysis, By Country

 

6.3. Oral

 

6.3.1. Market Size And Forecast, By Region

6.3.2. Market Analysis, By Country

 

6.4. Topical

 

6.4.1. Market Size And Forecast, By Region

6.4.2. Market Analysis, By Country

 

Chapter 7: Psoriatic Arthritis Treatment Market, By Region

 

7.1. Overview

 

7.1.1. Market Size And Forecast

 

7.2. North America

 

7.2.1. Key Market Trends, Growth Factors, And Opportunities

7.2.2. Market Size And Forecast, By Country

 

7.2.2.1. U.S.

 

7.2.2.1.1. U.S. Psoriatic Arthritis Treatment Market, By Drug Type

7.2.2.1.2. U.S. Psoriatic Arthritis Treatment Market, By Type

7.2.2.1.3. U.S. Psoriatic Arthritis Treatment Market, By Route of Administration

 

7.2.2.2. Canada

 

7.2.2.2.1. Canada Psoriatic Arthritis Treatment Market, By Drug Type

7.2.2.2.2. Canada Psoriatic Arthritis Treatment Market, By Type

7.2.2.2.3. Canada Psoriatic Arthritis Treatment Market, By Route of Administration

 

7.2.2.3. Mexico

 

7.2.2.3.1. Mexico Psoriatic Arthritis Treatment Market, By Drug Type

7.2.2.3.2. Mexico Psoriatic Arthritis Treatment Market, By Type

7.2.2.3.3. Mexico Psoriatic Arthritis Treatment Market, By Route of Administration

 

7.2.3. North America Market Size And Forecast, By Drug Type

7.2.4. North America Market Size And Forecast, By Type

7.2.5. North America Market Size And Forecast, By Route of Administration

 

7.3. Europe

 

7.3.1. Key Market Trends, Growth Factors, And Opportunities

7.3.2. Market Size And Forecast, By Country

 

7.3.2.1. Germany

 

7.3.2.1.1. Germany Psoriatic Arthritis Treatment Market, By Drug Type

7.3.2.1.2. Germany Psoriatic Arthritis Treatment Market, By Type

7.3.2.1.3. Germany Psoriatic Arthritis Treatment Market, By Route of Administration7.3.2.2. France

7.3.2.2.1. France Psoriatic Arthritis Treatment Market, By Drug Type

7.3.2.2.2. France Psoriatic Arthritis Treatment Market, By Type

7.3.2.2.3. France Psoriatic Arthritis Treatment Market, By Route of Administration

 

7.3.2.3. Uk

 

7.3.2.3.1. Uk Psoriatic Arthritis Treatment Market, By Drug Type

7.3.2.3.2. Uk Psoriatic Arthritis Treatment Market, By Type

7.3.2.3.3. Uk Psoriatic Arthritis Treatment Market, By Route of Administration

 

7.3.2.4. Italy

 

7.3.2.4.1. Italy Psoriatic Arthritis Treatment Market, By Drug Type

7.3.2.4.2. Italy Psoriatic Arthritis Treatment Market, By Type

7.3.2.4.3. Italy Psoriatic Arthritis Treatment Market, By Route of Administration

 

7.3.2.5. Spain

 

7.3.2.5.1. Spain Psoriatic Arthritis Treatment Market, By Drug Type

7.3.2.5.2. Spain Psoriatic Arthritis Treatment Market, By Type

7.3.2.5.3. Spain Psoriatic Arthritis Treatment Market, By Route of Administration

 

7.3.2.6. Rest of Europe

 

7.3.2.6.1. Rest of Europe Psoriatic Arthritis Treatment Market, By Drug Type

7.3.2.6.2. Rest of Europe Psoriatic Arthritis Treatment Market, By Type

7.3.2.6.3. Rest of Europe Psoriatic Arthritis Treatment Market, By Route of Administration

 

7.3.3. Europe Market Size And Forecast, By Drug Type

7.3.4. Europe Market Size And Forecast, By Type

7.3.5. Europe Market Size And Forecast, By Route of Administration

 

7.4. Asia-Pacific

 

7.4.1. Key Market Trends, Growth Factors, And Opportunities

7.4.2. Market Size And Forecast, By Country

 

7.4.2.1. Japan

 

7.4.2.1.1. Japan Psoriatic Arthritis Treatment Market, By Drug Type

7.4.2.1.2. Japan Psoriatic Arthritis Treatment Market, By Type

7.4.2.1.3. Japan Psoriatic Arthritis Treatment Market, By Route of Administration

 

7.4.2.2. China

 

7.4.2.2.1. China Psoriatic Arthritis Treatment Market, By Drug Type

7.4.2.2.2. China Psoriatic Arthritis Treatment Market, By Type

7.4.2.2.3. China Psoriatic Arthritis Treatment Market, By Route of Administration

 

7.4.2.3. Australia

 

7.4.2.3.1. Australia Psoriatic Arthritis Treatment Market, By Drug Type

7.4.2.3.2. Australia Psoriatic Arthritis Treatment Market, By Type

7.4.2.3.3. Australia Psoriatic Arthritis Treatment Market, By Route of Administration

 

7.4.2.4. India

 

7.4.2.4.1. India Psoriatic Arthritis Treatment Market, By Drug Type

7.4.2.4.2. India Psoriatic Arthritis Treatment Market, By Type

7.4.2.4.3. India Psoriatic Arthritis Treatment Market, By Route of Administration

 

7.4.2.5. South Korea

 

7.4.2.5.1. South Korea Psoriatic Arthritis Treatment Market, By Drug Type

7.4.2.5.2. South Korea Psoriatic Arthritis Treatment Market, By Type

7.4.2.5.3. South Korea Psoriatic Arthritis Treatment Market, By Route of Administration

 

7.4.2.6. Rest of Asia-Pacific

 

7.4.2.6.1. Rest of Asia-Pacific Psoriatic Arthritis Treatment Market, By Drug Type

7.4.2.6.2. Rest of Asia-Pacific Psoriatic Arthritis Treatment Market, By Type

7.4.2.6.3. Rest of Asia-Pacific Psoriatic Arthritis Treatment Market, By Route of Administration

 

7.4.3. Asia-Pacific Market Size And Forecast, By Drug Type

7.4.4. Asia-Pacific Market Size And Forecast, By Type

7.4.5. Asia-Pacific Market Size And Forecast, By Route of Administration

 

7.5. Lamea

 

7.5.1. Key Market Trends, Growth Factors, And Opportunities

7.5.2. Market Size And Forecast, By Country

 

7.5.2.1. Brazil

 

7.5.2.1.1. Brazil Psoriatic Arthritis Treatment Market, By Drug Type

7.5.2.1.2. Brazil Psoriatic Arthritis Treatment Market, By Type

7.5.2.1.3. Brazil Psoriatic Arthritis Treatment Market, By Route of Administration

 

7.5.2.2. Saudi Arabia

 

7.5.2.2.1. Saudi Arabia Psoriatic Arthritis Treatment Market, By Drug Type

7.5.2.2.2. Saudi Arabia Psoriatic Arthritis Treatment Market, By Type

7.5.2.2.3. Saudi Arabia Psoriatic Arthritis Treatment Market, By Route of Administration

 

7.5.2.3. South Africa

 

7.5.2.3.1. South Africa Psoriatic Arthritis Treatment Market, By Drug Type

7.5.2.3.2. South Africa Psoriatic Arthritis Treatment Market, By Type

7.5.2.3.3. South Africa Psoriatic Arthritis Treatment Market, By Route of Administration

 

7.5.2.4. Rest of Lamea

 

7.5.2.4.1. Rest of Lamea Psoriatic Arthritis Treatment Market, By Drug Type

7.5.2.4.2. Rest of Lamea Psoriatic Arthritis Treatment Market, By Type

7.5.2.4.3. Rest of Lamea Psoriatic Arthritis Treatment Market, By Route of Administration

 

7.5.3. Lamea Market Size And Forecast, By Drug Type

7.5.4. Lamea Market Size And Forecast, By Type

7.5.5. Lamea Market Size And Forecast, By Route of Administration

 

Chapter 8: Company Profiles

 

8.1. Abbvie Inc.

 

8.1.1. Company Overview

8.1.2. Company Snapshot

8.1.3. Operating Business Segments

8.1.4. Product Portfolio

8.1.5. Business Performance

8.1.6. Key Strategic Moves And Developments

 

8.2. Amgen Inc.

 

8.2.1. Company Overview

8.2.2. Company Snapshot

8.2.3. Operating Business Segments

8.2.4. Product Portfolio

8.2.5. Business Performance

8.2.6. Key Strategic Moves And Developments

 

8.3. Bristol-Myers Squibb Company

 

8.3.1. Company Overview

8.3.2. Company Snapshot

8.3.3. Operating Business Segments

8.3.4. Product Portfolio

8.3.5. Business Performance

8.3.6. Key Strategic Moves And Developments

 

8.4. Eli Lilly And Company.

 

8.4.1. Company Overview

8.4.2. Company Snapshot

8.4.3. Operating Business Segments

8.4.4. Product Portfolio

8.4.5. Business Performance

8.4.6. Key Strategic Moves And Developments

 

8.5. Johnson & Johnson.

 

8.5.1. Company Overview

8.5.2. Company Snapshot

8.5.3. Operating Business Segments

8.5.4. Product Portfolio

8.5.5. Business Performance

8.5.6. Key Strategic Moves And Developments

 

8.6. Merck & Co Inc.

 

8.6.1. Company Overview

8.6.2. Company Snapshot

8.6.3. Operating Business Segments

8.6.4. Product Portfolio

8.6.5. Business Performance

 

8.7. Mylan N.V

 

8.7.1. Company Overview

8.7.2. Company Snapshot

8.7.3. Operating Business Segments

8.7.4. Product Portfolio

8.7.5. Business Performance

 

8.8. Novartis Ag

 

8.8.1. Company Overview

8.8.2. Company Snapshot

8.8.3. Operating Business Segments

8.8.4. Product Portfolio

8.8.5. Business Performance

 

8.9. Pfizer Inc.

 

8.9.1. Company Overview

8.9.2. Company Snapshot

8.9.3. Operating Business Segments

8.9.4. Product Portfolio

8.9.5. Business Performance

 

8.10. Ucb S.A.

 

8.10.1. Company Overview

8.10.2. Company Snapshot

8.10.3. Operating Business Segments

8.10.4. Product Portfolio

8.10.5. Business Performance


List Of Figure

List of Figures

 

Figure 01. Global Psoriatic Arthritis Treatment Market Segmentation

Figure 02. Top Investment Pockets

Figure 03. High Bargaining Power of Suppliers

Figure 04. Moderate Bargaining Power of Buyers

Figure 05. High Threat of Substitutes

Figure 06. Moderate Threat of New Entrants

Figure 07. High Intensity of Rivalry

Figure 08. Impact Analysis

Figure 09. Comparative Analysis of Nsaids Psoriatic Arthritis Treatment Market, By Country, 2018 & 2026 (USD Million)

Figure 10. Comparative Analysis of Dmards Psoriatic Arthritis Treatment Market, By Country, 2018 & 2026 (USD Million)

Figure 11. Comparative Analysis of Biologics Psoriatic Arthritis Treatment Market, By Country, 2018 & 2026 (USD Million)

Figure 12. Comparative Analysis of Others Psoriatic Arthritis Treatment Market, By Country, 2018 & 2026 (USD Million)

Figure 13. Comparative Analysis of Prescription Psoriatic Arthritis Treatment Market, By Country, 2018 & 2026 (USD Million)

Figure 14. Comparative Analysis of Otc Psoriatic Arthritis Treatment Market, By Country, 2018 & 2026 (USD Million)

Figure 15. Comparative Analysis of Injectable Psoriatic Arthritis Treatment Market, By Country, 2018 & 2026 (USD Million)

Figure 16. Comparative Analysis of Oral Psoriatic Arthritis Treatment Market, By Country, 2018 & 2026 (USD Million)

Figure 17. Comparative Analysis of Topical Psoriatic Arthritis Treatment Market, By Country, 2018 & 2026 (USD Million)

Figure 18. Abbvie Inc: Net Sales, 2016-2018 (USD Million)

Figure 19. Abbvie Inc: Revenue Share By Segment, 2018 (%)

Figure 20. Abbvie Inc: Revenue Share By Region, 2018(%)

Figure 21. Amgen: Net Sales, 2016-2018 (USD Million)

Figure 22. Amgen: Revenue Share By Region, 2018(%)

Figure 23. Bms: Net Sales, 2016-2018 (USD Million)

Figure 24. Bms: Revenue Share By Region, 2018(%)

Figure 25. Lilly: Net Sales, 2016-2018 (USD Million)

Figure 26. Lilly: Revenue Share By Segment, 2018 (%)

Figure 27. Lilly: Revenue Share By Region, 2018(%)

Figure 28. J&J: Net Sales, 2016-2018 (USD Million)

Figure 29. J&J: Revenue Share By Segment, 2018 (%)

Figure 30. J&J: Revenue Share By Geography, 2018 (%)

Figure 31. Merck & Co., Inc: Net Sales, 2016-2018 (USD Million)

Figure 32. Merck & Co., Inc: Revenue Share By Segment, 2018 (%)

Figure 33. Merck & Co., Inc: Revenue Share By Geography, 2018 (%)

Figure 34. Mylan: Net Sales, 2016-2018 (USD Million)

Figure 35. Mylan: Revenue Share By Geography, 2018 (%)

Figure 36. Novartis Ag: Net Sales, 2016-2018 (USD Million)

Figure 37. Novartis Ag: Revenue Share By Segment, 2018 (%)

Figure 38. Novartis Ag: Revenue Share By Region, 2018(%)

Figure 39. Pfizer Inc: Net Sales, 2016-2018 (USD Million)

Figure 40. Pfizer Inc: Revenue Share By Segment, 2018 (%)

Figure 41. Pfizer Inc: Revenue Share By Region, 2018(%)

Figure 42. Ucb S.A.: Net Sales, 2016-2018 (USD Million)

Figure 43. Ucb S.A.: Revenue Share By Segment, 2018 (%)

Figure 44. Ucb S.A.: Revenue Share By Geography, 2018 (%)


List Of Table

List of Tables

 

Table 01. Global Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026 (USD Million)

Table 02. Nsaids Psoriatic Arthritis Treatment Market, By Region, 2018-2026 (USD Million)

Table 03. Dmards Psoriatic Arthritis Treatment Market, By Region, 2018-2026 (USD Million)

Table 04. Biologics Psoriatic Arthritis Treatment Market, By Region, 2018-2026 (USD Million)

Table 05. Others Psoriatic Arthritis Treatment Market, By Region, 2018-2026 (USD Million)

Table 06. Global Psoriatic Arthritis Treatment Market, By Type, 2018-2026 (USD Million)

Table 07. Prescription Psoriatic Arthritis Treatment Market, By Region, 2018-2026 (USD Million)

Table 08. Otc Psoriatic Arthritis Treatment Market, By Region, 2018-2026 (USD Million)

Table 09. Global Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026 (USD Million)

Table 10. Injectable Psoriatic Arthritis Treatment Market, By Region, 2018-2026 (USD Million)

Table 11. Oral Psoriatic Arthritis Treatment Market, By Region, 2018-2026 (USD Million)

Table 12. Topical Psoriatic Arthritis Treatment Market, By Region, 2018-2026 (USD Million)

Table 13. Psoriatic Arthritis Treatment Market, By Region, 2018-2026 (USD Million)

Table 14. North America Psoriatic Arthritis Treatment Market, By Country, 2018-2026 (USD Million)

Table 15. U.S. Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026

Table 16. U.S. Psoriatic Arthritis Treatment Market, By Type, 2018-2026

Table 17. U.S. Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026

Table 18. Canada Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026

Table 19. Canada Psoriatic Arthritis Treatment Market, By Type, 2018-2026

Table 20. Canada Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026

Table 21. Mexico Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026

Table 22. Mexico Psoriatic Arthritis Treatment Market, By Type, 2018-2026

Table 23. Mexico Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026

Table 24. North America Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026

Table 25. North America Psoriatic Arthritis Treatment Market, By Type, 2018-2026

Table 26. North America Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026

Table 27. Europe Psoriatic Arthritis Treatment Market, By Country, 2018-2026 (USD Million)

Table 28. Germany Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026

Table 29. Germany Psoriatic Arthritis Treatment Market, By Type, 2018-2026

Table 30. Germany Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026

Table 31. France Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026

Table 32. France Psoriatic Arthritis Treatment Market, By Type, 2018-2026

Table 33. France Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026

Table 34. Uk Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026

Table 35. Uk Psoriatic Arthritis Treatment Market, By Type, 2018-2026

Table 36. Uk Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026

Table 37. Italy Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026

Table 38. Italy Psoriatic Arthritis Treatment Market, By Type, 2018-2026

Table 39. Italy Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026

Table 40. Spain Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026

Table 41. Spain Psoriatic Arthritis Treatment Market, By Type, 2018-2026

Table 42. Spain Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026

Table 43. Rest of Europe Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026

Table 44. Rest of Europe Psoriatic Arthritis Treatment Market, By Type, 2018-2026

Table 45. Rest of Europe Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026

Table 46. Europe Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026

Table 47. Europe Psoriatic Arthritis Treatment Market, By Type, 2018-2026

Table 48. Europe Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026

Table 49. Asia-Pacific Psoriatic Arthritis Treatment Market, By Country, 2018-2026 (USD Million)

Table 50. Japan Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026

Table 51. Japan Psoriatic Arthritis Treatment Market, By Type, 2018-2026

Table 52. Japan Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026

Table 53. China Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026

Table 54. China Psoriatic Arthritis Treatment Market, By Type, 2018-2026

Table 55. China Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026

Table 56. Australia Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026

Table 57. Australia Psoriatic Arthritis Treatment Market, By Type, 2018-2026

Table 58. Australia Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026

Table 59. India Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026

Table 60. India Psoriatic Arthritis Treatment Market, By Type, 2018-2026

Table 61. India Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026

Table 62. South Korea Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026

Table 63. South Korea Psoriatic Arthritis Treatment Market, By Type, 2018-2026

Table 64. South Korea Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026

Table 65. Rest of Asia-Pacific Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026

Table 66. Rest of Asia-Pacific Psoriatic Arthritis Treatment Market, By Type, 2018-2026

Table 67. Rest of Asia-Pacific Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026

Table 68. Asia-Pacific Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026

Table 69. Asia-Pacific Psoriatic Arthritis Treatment Market, By Type, 2018-2026

Table 70. Asia-Pacific Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026

Table 71. Lamea Psoriatic Arthritis Treatment Market, By Country, 2018-2026 (USD Million)

Table 72. Brazil Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026

Table 73. Brazil Psoriatic Arthritis Treatment Market, By Type, 2018-2026

Table 74. Brazil Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026

Table 75. Saudi Arabia Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026

Table 76. Saudi Arabia Psoriatic Arthritis Treatment Market, By Type, 2018-2026

Table 77. Saudi Arabia Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026

Table 78. South Africa Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026

Table 79. South Africa Psoriatic Arthritis Treatment Market, By Type, 2018-2026

Table 80. South Africa Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026

Table 81. Rest of Lamea Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026

Table 82. Rest of Lamea Psoriatic Arthritis Treatment Market, By Type, 2018-2026

Table 83. Rest of Lamea Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026

Table 84. Lamea Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026

Table 85. Lamea Psoriatic Arthritis Treatment Market, By Type, 2018-2026

Table 86. Lamea Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026

Table 87. Abbvie Inc: Company Snapshot

Table 88. Abbvie Inc: Operating Segments

Table 89. Abbvie Inc: Product Portfolio

Table 90. Amgen: Company Snapshot

Table 91. Amgen: Product Segment

Table 92. Amgen: Product Portfolio

Table 93. Bms.: Operating Segment

Table 94. Bms.: Product Portfolio

Table 95. Lilly: Company Snapshot

Table 96. Lilly: Operating Segments

Table 97. Lilly: Product Portfolio

Table 98. J&J: Company Snapshot

Table 99. J&J: Operating Segments

Table 100. J&J: Product Portfolio

Table 101. Merck & Co., Inc: Company Snapshot

Table 102. Merck & Co., Inc: Operating Segments

Table 103. Merck & Co., Inc: Product Portfolio

Table 104. Mylan: Company Snapshot

Table 105. Mylan: Operating Segments

Table 106. Mylan: Product Portfolio

Table 107. Novartis Ag: Company Snapshot

Table 108. Novartis Ag: Operating Segments

Table 109. Novartis Ag: Product Portfolio

Table 110. Pfizer Inc: Company Snapshot

Table 111. Pfizer Inc: Operating Segments

Table 112. Pfizer Inc: Product Portfolio

Table 113. Ucb S.A.: Company Snapshot

Table 114. Ucb S.A.: Product Portfolio

Single-User license:

This  grants one non-exclusive, non-transferable machine-readable license for the report either electronically or online. The right to store, display, use, or stockpile the report is restricted to only ONE authorized computer. For obtaining a single user license, ONLY an individual ("you") for individual use is entitled for using the product or as mentioned in the License Terms. Any individual representing an organization is refrained from accessing the products/services of AMR or as stated in the License Terms; any breach of which shall lead to violation of applicable laws in the United States, India, or in the jurisdiction of purchase. The products and services offered are the intellectual property of AMR, and are protected by applicable copyright laws, international treaty provisions, and other applicable laws of the country in which these are being used. Albeit the abovementioned, you are NOT be permitted to:

transmit or permit any third party to use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to assign the rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial/noncommercial gains

share the information or content either electronically or in printed form with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization or any other unauthorized users.

 

Five-User License:

This  grants up to Five non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online. The right to store, transfer, display, use, or stockpile the report is restricted to only FIVE authorized users. An individual representing an organization or an organization shall ONLY purchase the five-user license. The authorized users can print additional duplicate printed copies of the report for distribution to the employees of his/her company (Personnel). Albeit the abovementioned, you are NOT be permitted to:

 

transmit or permit by any means to any third party (i.e. non-personnel) or unauthorized users for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to redistribute or assign rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; exclusively permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial or noncommercial gains.

share the information or content either electronically or as printed copies with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization, or to more than 5 AUTHORIZED USERS.

 

Enterprise License:

This  grants global, non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online, within the organization and/or its subsidiaries. The authorized users shall have complete right to store, display, transfer, and/or use the report ONLY within the organization or its subsidiaries. Authorized users can take unlimited printed copies of the report for distribution among its employees. Albeit the abovementioned, you shall NOT be permitted to:

transmit or permit by any means to any third party (i.e. non-personnel) for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer or attempt to assign the rights in the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly And Company, Johnson & Johnson, Merck & Co Inc., Novartis AG, Pfizer Inc., and UCB S.A.